Guest Editors
Dr. Maria V. Deligiorgi
Email: mdeligiorgi@yahoo.com
Affiliation: Department of Pharmacology-Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str, Goudi, 11527, Athens, Greece.
Homepage:
Research Interests: Oncology; clinical pharmacology; cancer immunotherapy; immune checkpoint inhibitors; endocrinology; diabetes; metabolism; drug safety
Assoc. Prof. Marilita M. Moschos
Email: moschosmarilita@yahoo.fr
Affiliation: Department of Ophthalmology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
Homepage:
Research Interests: Electrophysiology of Vision, Glaucoma, Ocular adverse events related to immune checkpoint inhibitors, retinoblastoma, vitreoretinal lymphoma
Prof. Dimitrios T. Trafalis
Email: dtrafal@med.uoa.gr
Affiliation: Department of Pharmacology-Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
Homepage:
Research Interests: Cancer Research, Chemotherapy, Tumors, Cancer, Immunotherapy, Clinical pharmacology, Drug development
Summary
Nowadays, the cancer treatment paradigm is halfway towards an optimal trajectory of innovative modalities, among which the immune checkpoint inhibitors prevail.
Rewarding a long investigative journey, the immune checkpoint inhibitors can reinvigorate the tumor immune surveillance, revolutionizing the cancer treatment. The breathtaking pace of the incorporation of immune checkpoint inhibitors in the oncologists’ arsenal has brought into the spotlight two major hurdles: (i) tumor resistance, and (ii) immune-related adverse events.
The pivotal question is how to overcome these hurdles and entrench the clinical success of immune checkpoint inhibitors. In that respect, burgeoning research is advancing towards the development of more effective and safer immune checkpoint inhibitors.
This Special Issue aims to serve as a call to action to tackle current challenges, while opening new avenues concerning immune checkpoint inhibitors. We encourage an ongoing dialogue between researchers, clinicians, and readers that ensures the flow of knowledge from the laboratory to the clinic and vice versa to refine our understanding and inspire future opportunities for immune checkpoint inhibitors.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
· Unravelling new druggable immune checkpoints.
· Overcoming tumor resistance to immune checkpoint inhibitors.
· Leveraging nanotechnology and bioengineering for the development of novel immune checkpoint inhibitors.
· Utilizing the genomic and immune profiling of tumors to personalize treatment with immune checkpoint inhibitors.
· Harnessing artificial intelligence (AI) and analysis of large-scale protein data from tumor samples to personalize the treatment with immune checkpoint inhibitors.
· Understanding, predicting, and mitigating the immune-related toxicity.
Keywords
Neoplasms/therapy; Immunotherapy; Tumor Microenvironment; Programmed Cell Death 1 Receptor/immunology; CTLA-4 Antigen/immunology; Antibodies, Monoclonal/therapeutic use; Tumor Biomarkers; Treatment Outcome; Immune-related adverse events
Login
Register
Submit a Paper
Propose a Special lssue